New insights on the pathogenesis of endometriosis and novel non-surgical therapies

Area of Science:

• Reproductive Medicine
• Gynecology
• Pharmacology

Background:

• Endometriosis lacks a definitive pathogenetic model, leading to treatment challenges.
• Current endometriosis treatments primarily manage symptoms and fertility, often with significant side effects.
• Novel therapeutic agents and non-invasive techniques are being explored to improve endometriosis management.

Purpose of the Study:

• To provide insights into endometriosis pathogenesis.
• To review novel non-surgical treatment modalities for endometriosis.
• To evaluate the efficacy and safety of existing and emerging endometriosis therapies.

Main Methods:

• Literature review of novel therapeutic agents for endometriosis.
• Analysis of seven recognized treatment modalities: dienogest, aromatase inhibitors (AIs), gonadotrophin-releasing hormone (GnRH) antagonists, anti-tumor necrosis factor (TNF)-α, selective estrogen receptor modulators (SERMs), selective progesterone receptor modulators (SPRMs), and high-intensity focused ultrasound (HIFU).

Main Results:

• Dienogest, AIs, and GnRH antagonists demonstrate efficacy with favorable safety and tolerance profiles.
• SERMs and SPRMs exhibit inconsistent therapeutic results.
• Anti-TNF-α is currently in the animal experimental stage, and HIFU is a potential future treatment but not yet clinically applicable.

Conclusions:

• Novel agents like dienogest, AIs, and GnRH antagonists represent significant advancements in endometriosis treatment.
• Further research is needed for therapies such as SERMs, SPRMs, anti-TNF-α, and HIFU to establish their clinical utility.
• Developing effective and safe non-surgical treatments remains a priority for managing endometriosis.